Hi, this is the website of the NanoBioPhotonix Lab in Tel-Aviv university.
The main focus of the group is Single-molecule genomics but we have activity also in development of new optical detection schemes and novel imaging techniques. We explore genomes utilizing tools and reagents from the realm of nano-technology. We try learning new things about these systems by zooming in on individuals - single cells, single chromosomes and single molecules. Research in the lab is highly multi and inter disciplinary and our team is composed of chemists, biologists and physicists who are interested in learning from each other and doing some great (but sometimes risky...) stuff at the very forefront of science.
News
Welcome to the new Nano building!
9 Dec 2024
The Jan Koum Center for Nanoscience and Nanotechnology is a research facility focused on cutting-edge research and technological advancement.
It's all about Chemistry...
The podcast 'Tel Aviv-360' hosting Prof. Yuval Ebenstein
17 Nov 2024
Listen to this speacial episode with Prof. Ebenstein - What is 'Epigenetics' and How Do Our Emotions Affect DNA?
2 New publications in Blood jurnal
5 Nov 2024
Targeted, Low Cost Epigenetic Microarray for AML and MDS Detection & Detection of B Cell Lymphomas By a Simple Epigenetic Blood Test
Single-Molecule Sensors and NanoSystems International
Conference- S3IC Paris 2024
28-30 Oct 2024
The presentation of the paper- Single-molecule Toxicogenomics: Optical Genome Mapping of DNA-damage in nanochannel arrays by Prof. Ebenstein & the presentation of the paper-DeepQR: Single-molecule QR codes provide extreme multiplexing for optical gene-expression analysis by Dr. Jonathan Jeffet
LMI Students Seminar: Lanna & Jonathan Presenting
18 July 2024
Lanna Bery presenting 'High resolution spectral microscopy'
Jonathan Jeffet presenting 'DeepQR: single-molecule QR codes for optical gene-expression analysis'
Swedish Microfluidics in Life Sciences Conference – 4-5 June 2024
4 June 2024
The 2024 SMILS conference will be jointly hosted by the Department of Life Sciences at Chalmers and the Department of Physics at the University of Gothenburg.
One of the plenary speakers is Prof. Yuval Ebenstein.
Abstract published in Medrxiv
3 May 2024
Oxford Nanopore Technology (ONT) based methylation sequencing is increasingly recognized for its rapid and accurate classification of brain tumors. A process that is crucial for optimal patient treatment. However, widespread clinical utility is currently limited by the need for fresh-frozen biopsies and not the standard-of-care formalin-fixed, paraffin-embedded (FFPE) samples. Our study explores the impact of FFPE on DNA methylation and presents a developed and validated protocol for ONT-based FFPE tumor classification. We present a practical solution for precise brain tumor diagnoses in routine clinical settings and facilitating timely treatment decisions at the point of care and without interfering with operating room standards.
Abstract published in Biorxiv
1 April 2024
Carcinogenesis often involves significant alterations in the cancer genome architecture, marked by large structural and copy number variations (SVs and CNVs) that are difficult to capture with short-read sequencing. Traditionally, cytogenetic techniques are applied to detect such aberrations, but they are limited in resolution and do not cover features smaller than several hundred kilobases. Optical genome mapping and nanopore sequencing are attractive technologies that bridge this resolution gap and offer enhanced performance for cytogenetic applications. These methods profile native, individual DNA molecules, thus capturing epigenetic information. We applied both techniques to characterize a clear cell renal cell carcinoma (ccRCC) tumor's structural and copy number landscape, highlighting the relative strengths of each method in the context of variant size and average read length. Additionally, we assessed their utility for methylome and hydroxymethylome profiling, emphasizing differences in epigenetic analysis applicability.
Congratulations! The proposal for an ERC Proof of Concept Grant:
MiRACLE, has been selected for funding
18 January 2024
We got 150,000 Euros for our project: Multiplexed microRNA detection platform for early diagnosis and patient management.
The 65th ASH Annual Meeting Abstracts - Abstract published in Blood
28 November 2023
Acute Myeloid Leukemia (AML) is marked by uncontrolled growth of undifferentiated myeloid cells. DNA methylation patterns in AML have been thoroughly researched, however, studies on hydroxy methylation patterns, indicating active DNA methylation erasure, are still evolving. Our principal goal was to detect differential methylation and hydroxy methylation regions between AML and non-malignant samples. We proposed that simultaneous profiling of blood cells and circulating cell-free DNA would offer more insights into the disease mechanism. Therefore, we combined these data sources to provide a comprehensive epigenetic picture, assuming that this dual approach could reveal new AML biomarkers and enhance our understanding regarding AML pathobiology.
Single-Molecule Sensors and NanoSystems International Conference – S3IC 2023, Barcelona
23 November 2023
The presentation of the abstract- "Machine learning based Singlemolecule Quantification of Circulating Micro RNA Mixtures"
Article published in ChemBioChem
17 October 2023
5-Methylcytosine and 5-hydroxymethylcytosine are epigenetic modifications involved in gene regulation and cancer. We present a new, simple, and high-throughput platform for multi-color epigenetic analysis. The novelty of our approach is the ability to multiplex methylation and de-methylation signals in the same assay. We utilize an engineered methyltransferase enzyme that recognizes and labels all unmodified CpG sites with a fluorescent cofactor. In combination with the already established labeling of the de-methylation mark 5-hydroxymethylcytosine via enzymatic glycosylation, we obtained a robust platform for simultaneous epigenetic analysis of these marks. We assessed the global epigenetic levels in multiple samples of colorectal cancer and observed a 3.5-fold reduction in 5hmC levels but no change in DNA methylation levels between sick and healthy individuals. We also measured epigenetic modifications in chronic lymphocytic leukemia and observed a decrease in both modification levels (5-hydroxymethylcytosine: whole blood 30 %; peripheral blood mononuclear cells (PBMCs) 40 %. 5-methylcytosine: whole blood 53 %; PBMCs 48 %). Our findings propose using a simple blood test as a viable method for analysis, simplifying sample handling in diagnostics. Importantly, our results highlight the assay‘s potential for epigenetic evaluation of clinical samples, benefiting research and patient management.